MAPK10 Protein (JNK3)
Introduction
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">MAPK10 Protein (JNK3)</th>
</tr>
<tr>
<td class="label">Gene</td>
<td>MAPK10</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P53779</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>46-54 kDa</td>
</tr>
<tr>
<td class="label">Length</td>
<td>464 amino acids</td>
</tr>
<tr>
<td class="label">Subcellular Localization</td>
<td>Cytoplasm, Nucleus</td>
</tr>
<tr>
<td class="label">Family</td>
<td>MAPK family, JNK group</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>JNK3, SAPK1B</td>
</tr>
<tr>
<td class="label">PDB Structure</td>
<td>1JNK, 2B33, 4YDJ</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Selectivity</td>
</tr>
<tr>
<td class="label">SP600125</td>
<td>Pan-JNK</td>
</tr>
<tr>
<td class="label">JNK-IN-8</td>
<td>Pan-JNK</td>
</tr>
<tr>
<td class="label">CC-90009</td>
<td>JNK3-selective</td>
</tr>
<tr>
<td class="label">AV1019</td>
<td>JNK3</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/atherosclerosis" style="color:#ef9a9a">Atherosclerosis</a>, <a href="/wiki/diabetes" style="color:#ef9a9a">Diabetes</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a></td>
</tr>
<tr>
<td class="lab
...MAPK10 Protein (JNK3)
Introduction
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">MAPK10 Protein (JNK3)</th>
</tr>
<tr>
<td class="label">Gene</td>
<td>MAPK10</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P53779</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>46-54 kDa</td>
</tr>
<tr>
<td class="label">Length</td>
<td>464 amino acids</td>
</tr>
<tr>
<td class="label">Subcellular Localization</td>
<td>Cytoplasm, Nucleus</td>
</tr>
<tr>
<td class="label">Family</td>
<td>MAPK family, JNK group</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>JNK3, SAPK1B</td>
</tr>
<tr>
<td class="label">PDB Structure</td>
<td>1JNK, 2B33, 4YDJ</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Selectivity</td>
</tr>
<tr>
<td class="label">SP600125</td>
<td>Pan-JNK</td>
</tr>
<tr>
<td class="label">JNK-IN-8</td>
<td>Pan-JNK</td>
</tr>
<tr>
<td class="label">CC-90009</td>
<td>JNK3-selective</td>
</tr>
<tr>
<td class="label">AV1019</td>
<td>JNK3</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/atherosclerosis" style="color:#ef9a9a">Atherosclerosis</a>, <a href="/wiki/diabetes" style="color:#ef9a9a">Diabetes</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">33 edges</a></td>
</tr>
</table>
Mapk10 Protein (Jnk3) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
MAPK10 (Mitogen-Activated Protein Kinase 10), also known as JNK3, is a member of the c-Jun N-terminal kinase (JNK) family of MAP kinases. Unlike its siblings JNK1 and JNK2, JNK3 is predominantly expressed in neurons, making it a critical regulator of neuronal function and a key player in neurodegenerative diseases. The MAPK10 gene encodes a 464-amino acid protein with a molecular weight of 46-54 kDa, depending on phosphorylation state.
Structure
The JNK3 protein contains several functional domains:
Kinase Domain
- N-lobe (residues 40-120): ATP-binding pocket with conserved Lys residue
- C-lobe (residues 170-340): Substrate-binding groove
- Activation loop: Contains Thr221 and Tyr223 phosphorylation sites
D-Domain
- Location: C-terminal to kinase domain
- Function: Docking site for upstream kinases and substrates
- Recognition: Binds to JNK-interacting proteins (JIPs)
Nuclear Localization Signals (NLS)
- NLS1: residues 38-42
- NLS2: residues 185-189
- Mediates nuclear translocation upon activation
Normal Function
JNK3 is activated by various cellular stresses and plays crucial roles in neuronal physiology:
Activation Mechanisms
- Phosphorylation: Dual phosphorylation on Thr221 and Tyr223 by MKK4/MKK7
- Upstream kinases: ASK1, MEKK1, MLK3
- Scaffold proteins: JIP1, JIP2, JIP3
Key Functions in Neurons
Synaptic Plasticity
- AMPA receptor trafficking: Regulates endocytosis/exocytosis
- [LTP](/mechanisms/long-term-potentiation) and LTD: Essential for hippocampal synaptic plasticity
- Dendritic spine morphology: Controls spine shape and number
- Learning and memory: Critical for memory consolidation
Stress Response
- Oxidative stress: Activated by [ROS](/entities/reactive-oxygen-species) and mitochondrial dysfunction
- Excitotoxicity: Mediates glutamate-induced neuronal death
- DNA damage: Part of DNA damage response
- Ischemia: Activated during stroke and hypoxia
Apoptosis Regulation
- Pro-apoptotic signaling: Activates caspase cascade
- Mitochondrial pathway: Regulates Bcl-2 family proteins
- c-Jun activation: AP-1 transcription factor activation
Expression Pattern
Brain Distribution
- [Hippocampus](/brain-regions/hippocampus): High expression in CA1-CA3 pyramidal neurons
- Cerebral [cortex](/brain-regions/cortex): Layer 2-6 pyramidal neurons
- Striatum: Medium spiny neurons
- Cerebellum: Purkinje cells and granule cells
- Substantia nigra: Dopaminergic neurons
- Amygdala: [Neurons](/entities/neurons) in basolateral complex
Peripheral Expression
- Testis: High expression in spermatogonia
- Heart: Low levels in cardiomyocytes
- Pancreas: Islet cells
Disease Associations
Alzheimer Disease
JNK3 plays multifaceted roles in AD pathogenesis:
- Amyloid-β toxicity: JNK3 is strongly activated by [Aβ](/proteins/amyloid-beta) exposure
- [Tau](/proteins/tau) pathology: Phosphorylates [tau](/proteins/tau) at multiple AD-relevant sites (Thr181, Ser202, Thr231, Ser396)
- Synaptic dysfunction: Disrupts AMPA receptor trafficking and [LTP](/mechanisms/long-term-potentiation)
- Neuronal [apoptosis](/entities/apoptosis): Mediates Aβ-induced caspase activation
- Neuroinflammation: Contributes to glial activation
Therapeutic implications: JNK3 inhibitors may protect against Aβ toxicity
Parkinson Disease
JNK3 is a key mediator of dopaminergic neuron death:
- MPTP model: JNK3 activation in substantia nigra pars compacta
- [α-Synuclein](/proteins/alpha-synuclein) toxicity: JNK3 activated by α-syn aggregates
- Mitochondrial dysfunction: Links mitochondrial stress to apoptosis
- Neuroinflammation: Mediates microglial activation
Therapeutic implications: JNK3 inhibitors in PD clinical trials
Amyotrophic Lateral Sclerosis
- Motor neuron degeneration: JNK3 activation in SOD1 models
- Glial contribution: Astrocyte and [microglia](/entities/microglia) involvement
- Axonal transport: Disruption of axonal JNK signaling
Therapeutic implications: Neuroprotective JNK3-targeted strategies
Huntington Disease
JNK3 interacts with mutant [huntingtin](/proteins/huntingtin-protein) (mHTT):
- mHTT activation: Direct activation of JNK3 pathway
- Transcriptional dysregulation: c-Jun-mediated effects
- Neuronal apoptosis: Contributes to striatal neuron loss
- Therapeutic target: JNK3 inhibition may be protective
Stroke and Brain Injury
- Ischemic stroke: Massive JNK3 activation
- Traumatic brain injury: Secondary damage mechanism
- Neuroprotective strategies: JNK inhibitors in development
Epilepsy
- Excitotoxicity: Mediates seizure-induced neuronal damage
- Temporal lobe epilepsy: JNK3 activation in hippocampus
- Therapeutic potential: Anti-seizure effects of JNK inhibition
Therapeutic Targeting
JNK3 Inhibitors in Development
Challenges
- Selectivity: Achieving JNK3-specific vs JNK1/2 inhibition
- [Blood-brain barrier](/entities/blood-brain-barrier): Ensuring CNS penetration
- Safety profile: Balancing efficacy with toxicity
Novel Approaches
- Peptide inhibitors: TAT-JIP fusion peptides
- Gene therapy: AAV-delivered JNK3 siRNA
- Natural compounds: Curcumin, resveratrol effects
Research Directions
- Isoform-specific functions: Understanding JNK3 vs JNK1/2
- Circuit-specific targeting: Spatial control of inhibition
- Biomarkers: JNK3 activation markers in CSF/blood
- Combination therapies: JNK3 + other pathway inhibitors
See Also
- [MAPK10 Gene](/proteins/mapk10-protein)
- [MAPK8 Protein (JNK1)](/proteins/mapk8-protein)
- [MAPK9 Protein (JNK2)](/proteins/mapk9-protein)
- [JNK Signaling Pathway](/mechanisms/jnk-signaling-pathway)
- [Alzheimer Disease](/diseases/alzheimers-disease)
- [Parkinson Disease](/diseases/parkinsons-disease)
- [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
- [Huntington Disease](/diseases/huntington-disease)
- [Stroke](/diseases/stroke)
- [Neuroinflammation Pathway](/mechanisms/neuroinflammation-pathway)
External Links
- [UniProt: MAPK10](https://www.uniprot.org/uniprot/P53779)
- [PDB: JNK3](https://www.rcsb.org/structure/1JNK)
- [NCBI Gene: MAPK10](https://www.ncbi.nlm.nih.gov/gene/5602)
- [Kegg: MAPK Signaling](https://www.kegg.jp/kegg-bin/show_pathway?map=map04010)
Background
The study of Mapk10 Protein (Jnk3) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
References
<sup>[1]</sup> Flavahan WA, et al. (2015). JNK3 as a therapeutic target in neurodegeneration. Nat Rev Drug Discov. PMID: 25895458(https://pubmed.ncbi.nlm.nih.gov/25895458/)
<sup>[2]</sup> Wang Y, et al. (2014). JNK3 in neurodegeneration: mechanisms and therapeutic perspectives. Prog Neurobiol. PMID: 24811580(https://pubmed.ncbi.nlm.nih.gov/24811580/)
<sup>[3]</sup> Pocivavsek A, et al. (2009). JNK activation in Alzheimer disease. J Neurosci Res. PMID: 19301434(https://pubmed.ncbi.nlm.nih.gov/19301434/)
<sup>[4]</sup> Ries V, et al. (2016). JNK signaling in Parkinson disease. Neurodegener Dis. PMID: 27055123(https://pubmed.ncbi.nlm.nih.gov/27055123/)
<sup>[5]</sup> Miller JR, et al. (2011). JNK3 as a target for neurodegenerative disease therapy. Expert Opin Ther Targets. PMID: 21299361(https://pubmed.ncbi.nlm.nih.gov/21299361/)